Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148128 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
A Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, sponsored by Auricula Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 4
- Study locations
NCT07148128: Recruiting Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, sponsored by Auricula Biosciences.
NCT07148128 is a Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma that is actively recruiting participants, run by Auricula Biosciences. The registered enrollment target is 110 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (44% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07148128, a Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by Auricula Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
Primary Outcome
Type, incidence and severity of TEAEs, SAEs and abnormal laboratory values per CTCAE v5.0. Frequency of dose interruptions, reductions, and discontinuations. Proportion of participants with DLTs at each dose level.
Conditions Studied
Interventions
- DRUG WEF-001
Study Locations (4)
Texas
- NEXT Oncology Dallas - Dallas
- Next Oncology, San Antonio - San Antonio
Ontario
- Princess Margareth Cancer Center - Toronto
Oxford
- Oxford University Hospital - Headington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-07-28 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
What NCT07148128 shows while recruiting
NCT07148128 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (44% lower).
The record links to 5 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which WEF-001 is the first listed.
NCT07148128 reports a single indexed study location in Texas, Ontario, Oxford.
Frequently Asked Questions
What is clinical trial NCT07148128 about?
NCT07148128 is a clinical study titled "Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.". This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
What is the current status of trial NCT07148128?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2025-07-28. Estimated completion is 2028-01.
What conditions does trial NCT07148128 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced or Metastatic KRAS-mutant Tumor.
What interventions are being tested in trial NCT07148128?
The interventions under investigation include: WEF-001 (DRUG).
Who is sponsoring clinical trial NCT07148128?
This trial is sponsored by Auricula Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07148128 being conducted?
This trial has 4 study locations across Texas, Ontario, Oxford. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07148128's enrollment target sits among peer trials
110 77th of 144 higher than 67 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI